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Abstract
Background: Diffusely infiltrating astrocytomas originate from astrocytic glial cells or their precursor cells and are
the most common type of brain tumors in adults. In this retrospective study, we investigated the content of
hyaluronan, its cell surface receptor, CD44 and the expression of hyaluronan metabolizing enzymes, in these
aggressive tumors. Hyaluronan is the main component of extracellular matrix in the brain. In many tumors, aberrant
hyaluronan metabolism implicates aggressive disease progression and metastatic potential.
Methods: Our material consisted of 163 diffusely infiltrating astrocytomas (WHO grades II-IV). Tumor samples were
processed into tissue microarray (TMA) blocks. The TMA sections were stained for hyaluronan, CD44, hyaluronan
synthases 1–3 (HAS1–3) and hyaluronidase 2 (HYAL2). The immunostaining results were compared with χ2 –test or
with Kruskal-Wallis test for correlation with clinicopathological parameters and survival analyses were done with
Kaplan-Meier log rank test and Cox regression.
Results: Hyaluronan and CD44 were strongly expressed in astrocytic gliomas but their expression did not correlate
with WHO grade or any other clinicopathological parameters whereas high HAS2 staining intensity was observed in
IDH1 negative tumors (p = 0.003). In addition, in non-parametric tests increased HAS2 staining intensity correlated with
increased cell proliferation (p = 0.013) and in log rank test with decreased overall survival of patients (p = 0.001). In the
Cox regression analysis HAS2 expression turned out to be a significant independent prognostic factor (p = 0.008).
Conclusions: This study indicates that elevated expression of HAS2 is associated with glioma progression and suggests
that HAS2 has a prognostic significance in diffusely infiltrating astrocytomas.
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Background
Hyaluronan is a large glycosaminoglycan composed of re-
petitive units of N-acetylglucosamine and glucuronic acid.
In mammalian cells, there are three hyaluronan synthases
(HAS1, HAS2 and HAS3) which produce various sizes of
hyaluronan in the inner leaflet of the plasma membrane.
During its synthesis, hyaluronan is directly extruded
through the plasma membrane to the cell surface or into
the extracellular matrix [1]. Connective tissues contain the
largest amounts of hyaluronan, but it is synthesized abun-
dantly also in other tissues, including central nervous
system [2]. In vitro, hyaluronan increases migration of as-
trocytes which depends on hyaluronan receptor CD44 [3].
During brain development hyaluronan has an essential
role in the migration of neural cells [4]. In many cancers,
alterations in hyaluronan content and metabolism affect
progression and prognosis of disease [5–8]. In breast can-
cer, high levels of HAS1–3 in stromal cells associate with
decreased survival [9]. Silencing of HAS2 correlates with
increased expression of tissue metalloproteinase inhibitor
1 (TIMP-1) leading into decreased invasive capability in
breast cancer cells [10].
Gliomas originate from different types of neuroglial
cells or their precursors. Diffusely infiltrating astrocyto-
mas are the most common type of gliomas. They are
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divided into three categories (grades II-IV) by WHO
[11, 12]. Human glioma cell lines produce hyaluronan
and CD44, which are essential for adhesion, invasion
and migration of glioma cells [13–15]. It has been proposed
that aggressiveness of glioblastoma cell lines depends on
the co-expression of HASes and hyaluronidases [16]. More-
over, it has been reported that in high grade astrocytomas
(grades III-IV) the expression of CD44 is elevated [14].
Knockdown of CD44 in glioblastoma cell lines decreases
tumor growth and sensitizes them to cytotoxic drugs [17].
Although the functions of hyaluronan and CD44 have
been previously investigated in gliomas in vitro, the roles
of HASes and HYALs are unclear. Here we studied the
expression of hyaluronan related proteins in diffusely in-
filtrating astrocytomas, and compared the results with
histopathological and clinical parameters.
Methods
This retrospective study consisted of 163 WHO grade II-IV
diffusely infiltrating astrocytomas. Clinical data was ob-
tained from 150 patients (Table 1). Samples without clinical
information were excluded from the statistical analyses.
Samples were obtained with maximal safe resection from
surgically operated patients at the Tampere University
Hospital, Tampere, Finland, during 1983–2001. Data on
radio- and chemotherapy was known in 105 and 101 pa-
tients, respectively. Of these, 25 received only radiotherapy,
whereas 16 received only chemotherapy. Forty-three
patients received both radio- and chemotherapy. Forty-six
patients received also Temozolomide treatment for pro-
gressive astrocytoma. Follow-up time ranged from 0.1 to
83.4 months (mean follow-up 18.0 months) (Table 1).
The final study material included 25 grade II diffuse as-
trocytomas, 6 grade III anaplastic astrocytomas and 119
grade IV glioblastomas (including 3 gliosarcomas). Sam-
ples included both primary and recurred astrocytomas.
Histopathological analyses and grading were performed in
Fimlab Laboratories at Tampere University Hospital. Pro-
liferation was analysed with Ki-67 staining (MIB1), isoci-
trate dehydrogenase 1 (IDH1) mutation with R132H point
mutation-specific mouse monoclonal antibody (Dianova
GmbH, Hamburg, Germany), EGFR amplification with
chromogenic in situ hybridisation (CISH) and p53 status
with immunohistochemistry (antibody: DO-7, Novocastra
Laboratories, Newcastle, UK) as described previously
[18, 19]. The histopathological stainings were analysed by
experienced pathologists in Fimlab Laboratories at Tam-
pere University Hospital. IDH1 status was evaluated by
whether there were IDH1-R132H -positive tumor cells in
astrocytomas (Additional file 1: Figure S1). Brain tumor
samples were formalin-fixed, paraffin-embedded and
processed into tissue microarray blocks (TMA) [19]. The
study protocol was approved by Ethical Board of Northern
Savo Hospital District 108/2010, Ethical Committee of Tam-
pere University Hospital, National Authority for Medicolegal
Affairs of Finland and VALVIRA 9121/2010. The material
also included two normal human cerebral brain tissue speci-
mens from the Kuopio University Hospital obtained from
areas adjacent to tumor tissue.
Table 1 Clinicopathological characteristics of the diffusely infiltrating astrocytoma patients (n = 150) according to WHO classification
Variable Grade II Grade III Grade IV Total
Number of cases 25 (16.7%) 6 (4.0%) 119 (79.3%) 150 (100.0%)
Gender
Male 20 (80.0%) 1 (16.7%) 66 (55.5%) 87 (58.0%)
Female 5 (20.0%) 5 (83.3%) 53 (44.5%) 63 (42.0%)
Mean age at time of diagnosis (years) 40.6 46.2 58.3 54.8
Mean survival time (months) 36.5 29.5 13.4 18.0
Alive
Yes 9 (36.0%) 2 (33.3%) 6 (5.0%) 17 (11.3%)
No 16 (64.0%) 3 (50.0%) 108 (90.8%) 127 (84.7%)
No information 0 (0.0%) 1 (16.7%) 5 (4.2%) 6 (4.0%)
Cause of death
Glioma 16 (100.0%) 3 (100.0%) 108 (100.0%) 127 (100.0%)
Other causes 0 (0.0%) 0 (0.0%) 0 (0.0%)
Surgical operation
No 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%)
Resection 21 (84.0%) 6 (100.0%) 114 (95.8%) 141 (94.0%)
Biopsy 4 (16.0%) 0 (0.0%) 4 (3.4%) 8 (5.3%)
No information 0 (0.0%) 0 (0.0%) 1 (0.8%) 1 (0.7%)
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Hyaluronan and CD44 stainings
Hyaluronan staining was performed similarly as in our
previous work using a biotinylated hyaluronan-binding
complex (bHABC) [8]. The specificity of the bHABC
staining was controlled by Streptomyces hyaluronidase
(data not shown). The staining for CD44 was done with
Hermes3 antibody (a kind gift from Dr. Sirpa Jalkanen,
University of Turku, Finland) as previously described [8].
HAS1–3 and HYAL2 stainings
To detect HAS1–3 and hyaluronidase 2 in astrocytomas,
specimens were incubated with goat polyclonal antibodies
for HAS1–3 diluted in 1% BSA (HAS1 antibody 1:100,
HAS2 antibody 1:120 and HAS3 antibody 1:80 dilution,
Santa Cruz Biotechnology, Santa Cruz, CA) or with rabbit
polyclonal antibody for HYAL2 (1100 Abcam, Cambridge,
UK). The stainings were performed as described previ-
ously [8]. Tissue sections without the primary antibodies
were used as negative controls. The specificity of HAS2
antibody was tested with peptide-blocking (sc-34,067 P for
HAS2, Santa Cruz Biotechnology) in the glioma samples
(Additional file 2: Figure S2).
Evaluation of stainings
Intensity of stained TMA samples was estimated with a
four-level scoring system (0 = negative, 1 = weak, 2 =
moderate and 3 = strong staining intensity). Scoring of
slides was performed independently by two researchers.
The coverage of the stained tumor cells was evaluated as
follows: 0 = under 5% (considered negative), 1 = 6–25%,
2 = 26–75% and 3 = over 76% of cells stained. Staining
coverage and intensity results were combined creating a
new variable, the staining INDEX. The INDEX-values
were computed as follows: The staining intensity was
multiplied with the coverage of the stained cells, thus
the INDEX-values ranged from 0 to 9.
Statistical analyses
Statistical analyses were done with SPSS Statistics (IBM
SPSS Statistics 21.0) in Tampere University Hospital.
Association between immunostainings and histopathological
parameters were analysed with χ2 and Kruskal-Wallis test.
Survival analyses were performed with Kaplan-Meier log
rank test and Cox regression model. P-values < 0.05 were
considered statistically significant.
Results
Hyaluronan and CD44 are mainly localized in white
matter in normal brain tissue.
Cerebral brain tissue samples adjacent to tumor areas
with some visible gliosis showed abundant staining for
hyaluronan and CD44 (Fig. 1a, c). Both were mainly
localized in the white matter (Fig. 1b, c). Neurons in the
cortical areas were mostly negative or showed weak
staining for hyaluronan and CD44 (Fig. 1a, c, and d insert,
red arrows). CD44 localized strongly around perivascular
areas, especially astrocytes showed intense CD44 immu-
nopositivity (Fig. 1d, black arrows). In cortical brain,
HAS2 expression was relatively low, but some of the glial
cells and neurons were HAS2 –positive (Fig. 1e, black
arrows). Interestingly, HYAL2 immunostaining was
opposite to hyaluronan and CD44 (Fig.1f), localizing
mainly in the cortical areas (Fig. 1f) whereas the white
matter was negative for it. Glial cells were HYAL2 positive
and in cortical capillaries, endothelial cells showed intense
HYAL2 staining (Fig. 1f, white arrows).
Hyaluronan and CD44 are abundantly stained in diffusely
infiltrating astrocytomas
Hyaluronan and CD44 staining intensities were recorded
from 136 and 120 specimens, respectively. Hyaluronan
and CD44 showed intense membranous and cytoplasmic
staining (Fig. 2a-d). 57% (77/136) and 42% (50/120) of the
samples showed high hyaluronan and CD44 staining in-
tensity respectively (Fig. 4a, b). Especially high CD44
staining was observed around vascular structures (Fig. 2d,
insert). Hyaluronan or CD44 did not associate with WHO
grade even when grade II-III tumors were combined and
compared with grade IV tumors.
HYAL2 staining intensity was recorded from 133
(grade II = 21, grade III = 6 and grade IV = 106) samples.
HYAL2 staining intensities were mostly weak (81/133)
or moderate (29/133) (Fig. 2e, f and 4c). HYAL2 staining
was mainly cytoplasmic, and it was also seen in endothelial
cells (Fig. 2e, f). 25% (27/106) of grade IV tumors were
moderately stained with HYAL2, whereas 7.4% (2/27) of
grade II-III tumors had moderate HYAL2 staining (Fig. 4c).
Increased HYAL2 staining intensities and increased
HYAL2-INDEX values (n = 132) were associated with in-
creased WHO grade (p = 0.049 and p = 0.001, respectively).
When grade II-III tumors were combined and compared
with grade IV tumors differences were not statistically
significant.
Elevated immunostaining intensities of HAS1–2 associate
with increased WHO grade
All HASes were expressed in diffusely infiltrating astro-
cytomas. HAS2 was the most prevalent isoform localiz-
ing diffusely in the cytoplasm and near the cell surface
(Fig. 3c, d and 4e). HAS1 showed diffuse and granular
staining pattern and it mainly localized in the cytoplasm
but also occasional plasma membrane immunopositivity
was observed (Fig. 3b). HAS1 staining intensity (n = 129)
was not associated with WHO grade. However, grade IV
tumors (n = 103) had increased HAS1 staining intensities
compared to grade II-III tumors combined (n = 26). 46%
(12/26) of grade II-III tumors were HAS1 negative and
50% (13/26) had weak HAS1 staining. 20% (21/103) of
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grade IV tumors were HAS1 negative, 58% (60/103)
showed weak immunostaining and 20% (21/103) moderate
staining intensity (p = 0.026, Fig. 4d).
HAS2 staining intensity was recorded from 123
specimens (grade II = 19, grade III = 6, grade IV = 98).
Increased HAS2 immunostaining intensity was associ-
ated with higher WHO grade (p = 0.044, Fig. 4e). 53%
(52/98) of grade IV tumors, 33% (2/6) of grade III tu-
mors and 21% (4/19) of grade II tumors had moder-
ate staining intensity. In other words, 72% (18/25) of
grade II-III tumors were weakly stained for HAS2,
whereas in grade IV tumors only 38% (37/98) were
weakly stained (p = 0.009) (Fig. 4e). HAS2-INDEX was
higher in grade IV tumors compared with grade II-III
tumors combined (p = 0.015).
HAS3 immunostaining was the weakest of three
HASes (Fig. 3e, f ). Most of the samples were either
negative (56/123) or weakly (64/123) HAS3 positive
(n = 123) (Fig. 4f ). There were no differences between
the groups.
IDH1 mutation associates with low HAS2 immunostaining
in diffusely infiltrating astrocytomas
In our material, IDH1 mutation was associated with low
HAS2 intensity (21 IDH1-mutation positive and 89 wild
type IDH1) (p = 0.003, Fig. 5b). Furthermore, increased
intensity of HAS2 and HYAL2 were associated with
increased proliferation analysed with Ki-67 staining
(p = 0.013 and p = 0.010, respectively, Fig. 5a).
Fig. 1 Hyaluronan, CD44, HAS2 and HYAL2 stainings in brain tissue samples adjacent to tumor areas. Hyaluronan (a and b) staining intensity is higher
in white matter (b) than in the cortex (a). Likewise, CD44 (c and d) staining intensity is stronger in white matter than in the cortical areas (c). However,
there is noticeable CD44 staining in perivascular areas (d, d insert), where astrocytes show strong CD44 immunoreactivity. HAS2 staining is generally
weak (e), but there are some strongly HAS2 positive neurons and glial cells (black arrows, e insert). HYAL2 staining is more prominent in the cortical
areas whereas white matter is HYAL2 negative (f). Endothelial cells (white arrows) express strongly HYAL2 (f). Scale bar in F is 50 μm
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HAS1 intensity was associated with EGFR amplifica-
tion (p = 0.045, respectively, Chi-Square, Fig. 5b). EGFR
amplification status was reported in 81 tumors with
known HAS1 intensity value. EGFR amplification was
found in 23 tumors – most of them showed weak HAS1
staining intensity (19/23) (Fig. 5b). Tumors without
EGFR amplification had similar distribution of HAS1
intensity levels as in the whole material.
Hyaluronan, CD44 and HAS3 did not associate with
any of the studied histopathological parameters (WHO
grade, IDH1, p53, proliferation, EGFR).
Increased HAS2 intensity associates with decreased
overall survival
In univariate analyses, higher HAS2 (n = 89) staining in-
tensity was associated strongly with decreased overall
survival time (p = 0.001, Fig. 6a), similarly as high
HAS2-INDEX values (n = 87, p = 0.009, Fig. 6b).
Because HAS2 intensity was associated with overall
survival in univariate analyses we performed multivariate
analysis. Variables used were: WHO grade, IDH1 muta-
tion status, p53, EGFR amplification and HAS2 staining
intensity. Sixty-two specimens with complete data were
included in the analysis. In the Cox multivariate analysis,
HAS2 staining intensity was the only significant inde-
pendent factor (p = 0.008, Hazard Ratio = 1.685, 95% CI
1.144–2.481 for HAS2 staining intensity, other variables
not significant in the final equation, n = 62, stepwise Cox
regression, Additional file 3: Table S1).
Discussion
Our results indicate that especially HAS2 and to a lesser
extent HYAL2 and HAS1 are involved in the progression
of diffusely infiltrating astrocytomas. The present work
shows that increased immunostaining intensities of
HAS1, HAS2 and HYAL2 associate with increased
Fig. 2 Hyaluronan, CD44 and HYAL2 stainings in grade II and grade IV astrocytomas. Hyaluronan (a and b) and CD44 (c and d) staining intensities are
strong both in grade II (a and c) and grade IV (b and d) astrocytomas. CD44 is markedly expressed in the perivascular areas (d, insert, black arrows).
HYAL2 staining intensity increases according to WHO grade (e and f). Endothelial cells show HYAL2 immunopositivity (e and f, black arrows). Scale bar
in F is 50 μm
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WHO grade of the tumors. Low HAS2 immunostaining
was associated with IDH1 mutation, a known positive
prognostic factor in diffusely infiltrating astrocytomas.
Increased intensities of HAS2 and HYAL2 were associ-
ated with increased tumor cell proliferation. Survival
analyses indicated that elevated HAS2 staining intensity
is associated with decreased overall survival of the pa-
tients and is an independent prognostic factor in infil-
trating astrocytoma.
Hyaluronan and CD44 have been shown to promote
glioma cell invasion, migration and adhesion [14, 15, 20].
In gliomas, the cleavage of CD44 is important for tumor
cell migration, invasion and adhesion and this is induced
by matrix metalloproteinase-9 (MMP-9) [21]. Hyaluronan,
on the other hand, increases migration of glioma cells via
up-regulation of osteopontin [20]. In our material both
hyaluronan and CD44 were abundantly expressed in all
WHO grade (II-IV) astrocytomas but there were no statis-
tically significant differences between the grades. In this
respect, our results are contradictory to a previous report
where CD44 expression was increased in high grade com-
pared to low grade astrocytomas [14]. Our material, how-
ever, had a higher number of cases. In general, high CD44
expression is linked to mesenchymal subtype of glioblast-
oma and this associates with poor prognosis [22]. Interest-
ingly, our results show that hyaluronan and CD44 do not
associate with prognosis or any tested histopathological
parameters.
Our present data shows that increased HAS2 immu-
nostaining intensity is a negative prognostic factor in
astrocytomas associating significantly with decreased
survival of patients both in univariate and multivariate
tests. In breast cancer cells knockdown of HAS2 inhibits
cell proliferation, migration and invasion, increases
apoptosis and number of the cells in G0/G1 cell cycle
arrest, while high HAS2 expression in stromal cells
associates with decreased survival [9, 23]. Decreased
hyaluronan synthesis due to knockdown of HAS2
Fig. 3 HAS1–3 immunostainings in grade II and grade IV astrocytomas. HAS1 staining intensity is higher in grade IV astrocytomas (b) than in
grade II astrocytomas (a). Results are similar for HAS2, the staining intensity is higher in grade IV astrocytomas (d) than in grade II astrocytomas
(c). HAS3 staining intensities are very weak or negative in grade II (e) and grade IV astrocytomas (f). Scale bar in F is 50 μm
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probably explains some of the anti-tumorigenic effects,
but HAS2 might harbor some other mechanisms too such
as regulating TGFβ-induced epithelial-mesenchymal tran-
sition or increasing cancer cell invasion by downregulation
of TIMP-1 [10, 24]. Thus HAS2 might utilize some
hyaluronan-independent mechanisms that increase cancer
cells tumorigenesis.
We also show that HAS1, HAS2 and HYAL2 are asso-
ciated with WHO grade, suggesting that they have a role
in tumor progression. At the moment, the knowledge
about the role of hyaluronan synthases and hyaluroni-
dases in diffusely infiltrating astrocytomas is rather
limited. Novak et al. (1999) showed that overexpression




Fig. 4 Hyaluronan, CD44, HYAL2, HAS1, HAS2 and HAS3 staining intensities in gliomas according to WHO grade. There are no statistically
significant differences between the groups in hyaluronan (a) and CD44 (b) stainings. Intensity of HYAL2 staining increases according to
WHO grade (c). HAS1 staining intensity is higher in grade IV astrocytomas compared to grade II and III astrocytomas (d). HAS2 staining
intensity increases in grade IV astrocytomas compared to grade II-III astrocytomas (e). Most of the samples are HAS3 negative or the
staining intensity is weak (f). * = p-value < 0.05, ** = p-value < 0.01
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Fig. 5 Associations with histopathological parameters. Increased intensities of HYAL2 and HAS2 associate statistically significantly with increased
proliferation rates (MIB1, Ki-67 positive cells) (p = 0.010 and p = 0.013, respectively) (a). HAS1 staining intensity associates with EFGR amplification
(b) and HAS2 staining intensity associates with IDH1-mutation (b)
a b
Fig. 6 Patient survival according to HAS2 staining intensity. Elevated HAS2 intensity (a) and high HAS2-INDEX (b) correlate with decreased overall
survival in diffusely infiltrating astrocytomas (p = 0.001, p = 0.009, Kaplan-Meier log-rank test)
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intracerebral tumor growth and increased tumor
vascularization [25]. Hyaluronidases favor cancer progres-
sion via production of hyaluronan fragments which
enhance cleavage of CD44 and thus induce cell motility.
Moreover, hyaluronan fragments promote angiogenesis and
increase expression of MMP9 and 13 [26–28]. Overexpres-
sion of HAS2 in murine astrocytoma cell lines, unable to
produce hyaluronidases, decreased cells capability to form
subcutaneous or intracranial tumors, indicating that the
activity of both HAS and HYAL are essential for glioma cell
invasion [16].
The present data showed that increased HAS2 and
HYAL2 intensities are associated with increased cell
proliferation. Previously it has been shown that
osteopontin-induced HAS2 expression leads to in-
creased hyaluronan synthesis, elevated proliferation
and anchorage-independent growth of breast cancer
cells [29]. These effects were reversed by inhibition of
HAS2 [29]. Similar results have been published with
prostate tumor cells [30]. Simpson and co-workers
have shown that co-expression of HYAL1 and HAS2
is the most favorable combination for tumor forma-
tion in vivo, and in vitro overexpression of HAS2
decreases the growth of tumor cells compared to con-
trols [30]. However, co-expression of HYAL1 and
HAS2 restored the growth of tumor cells to the same
level as control cells [30]. Thus, the results from our
work and others suggest that both increased hyaluro-
nan synthase and hyaluronidase activity are required
for tumorigenesis.
Glioma patients with IDH1 or IDH2 mutation have a
significantly better prognosis than patients with wild-type
IDH [31, 32]. Interestingly, our results indicated that low
HAS2 immunostaining intensity associates significantly
with IDH1 mutation. Tumors with IDH1-mutation
showed mostly weak HAS2 immunostaining intensity
compared to wild-type IDH tumors which were most
often moderately stained for HAS2. Similar association
has not been reported before.
One of the hallmarks of grade IV glioblastomas is in-
creased vascularity and many novel promising therapies
are antiangiogenic [33]. Low-molecular weight hyaluro-
nan induces angiogenesis facilitating tumor progression
[27, 34–36]. Endothelial cell tube formation is dependent
on hyaluronan and its receptors, like CD44 and receptor
for HA-mediated cell motility (RHAMM) [34, 36]. Fur-
thermore, overexpression of HYAL1 also increases angio-
genesis [37]. In our material, expression of CD44 was
localized around perivascular areas in tumor tissues. Simi-
lar findings have been reported previously with CD44 in
astrocytomas where CD44 deficiency led to decreased
angiogenesis in mouse model [14, 38]. Angiogenesis might
be one way by which hyaluronan and CD44 induce
aggressive behavior in diffusely infiltrating astrocytomas.
Conclusions
The present work demonstrates novel data about changes
in hyaluronan metabolism in diffusely infiltrating astrocy-
tomas. We show that HAS1, HAS2 and HYAL2 associate
with tumor grade (WHO II-IV), and HAS2 is a negative
prognostic factor in diffusely infiltrating astrocytomas.
The worsening of outcome can be linked to altered
hyaluronan metabolism in tumor microenvironment.
Moreover, our results show that there is an association
between low HAS2 immunostaining intensity and IDH1 –
mutation, which is a known positive prognostic factor in
diffusely infiltrating astrocytomas.
Additional files
Additional file 1: Figure S1. IDH1-R132H –immunostaining in grade II (a)
and grade IV tumors (b). Grade II astrocytomas contain several IDH1-R132H –
positive cells, while grade IV tumors, glioblastomas, are mostly negative for
IDH1-R132H –immunostaining. Scale bar 50 μm. (TIF 33050 kb)
Additional file 2: Figure S2. The specificity of the HAS2 stainings was
tested with pre-incubating the HAS2 antibody with peptide used in
immunization. In A (grade I subependymal giant cell astrocytoma) and C
(grade III astrocytoma) HAS2 immunostaining; brown color represents
HAS2 and blue indicates nuclei. In B (grade IV gliosarcoma) and D (the
grade III astrocytoma) HAS2 antibody was pretreated with peptide. Scale
bar 50 μm. (TIF 6383 kb)
Additional file 3: Table S1. p-values of the other coefficients used in
multivariate analyses. (DOCX 15 kb)
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